Recro Pharma, Inc. (REPH)

[johnstockmaster]

PR out encouraging trial results next leg begins here guys this is just moving like ANIK which has gone from $3 to $ 42 get in cheap and hold till December to $33

[johnstockmaster]

It will come fast two analysts have given target from $ 25 to 33

[Ado Trade]

REPH is taking off! My current short term price target it $12.50. - IMO

[Ado Trade]

I hope so. I'd be able to retire at the ripe age of 28 and start trading full time.

[johnstockmaster]

Target $ 33 in next eight weeks

[Ado Trade]

2 Bounces off the 15 minute 100 sma in the past two days, upward trend, and RSI at 62. This is set for a nice leg up. Can't wait for that $20 mark. -IMO

[protagonist12]

REPH

[johnstockmaster]

Told you buddy no looking back till $30 ,we are waiting for more approval and clinical data news which will take this to new heights every session these prices are still damn cheap

[johnstockmaster]

Watch for the skie

[protagonist12]

Should come back to earth as liquidity dries up.

[johnstockmaster]

This will move fast low float

[johnstockmaster]

No downward trend just watch $ 30 in next 6 months

[PennyStockpick]

shorted $REPH is looking really heavy! and is starting to head towards the downside

[PennyStockpick]

$REPH short, looks like its starting a downward trend.

[johnstockmaster]

First resistance $ 10

[ClarkKant]

Nice gap and run play the last 2 days but did not buy this one :(

[protagonist12]

They are hemorrhaging cash(i.e. secondary already in the works), are far behind on their trials and funding this deal through a 14% per-annum bridge loan despite having not achieved revenues to date. This is just a case of low float/irrational exuberance. I like co. but will wait it out until it gets back to 3s. And it will happen as long as they continue to fund operations with toxic financing.

[ospreyeye]

$REPH chart - huge 2 day move past the 200 DMA - busted through the upper Bollinger Band on large $Volume -

[ClarkKant]

Has been a nice 2-day play but looking toppy now.

[johnstockmaster]

Big deal $ 25 in next 6 months

[protagonist12]

Recro Pharma buys assets from Alkermes in a $170M deal

http://www.wsj.com/articles/alkermes-to-sell-georgia-facility-pain-drug-rights-to-recro-pharma-1425897623

[johnstockmaster]

A close friend who is close to market maker NSDQ

[protagonist12]

from who?

[johnstockmaster]

I hear $ 6 soon

[protagonist12]

REPH financing deal

Recro Pharma, Inc. (Nasdaq: REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post operative pain announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC (Aspire Capital). Under the new agreement, Recro has the right to sell up to $10 million in shares of common stock to Aspire Capital, subject to certain terms and conditions over a two-year period. The agreement represents an additional tool to provide the Company with additional capital and flexibility.

While we remain focused on our on-going Dex-IN Phase II trial in acute pain following surgery, this financing provides us with additional financial flexibility in anticipation of our upcoming interim and top-line results for our on-going trial, said Gerri Henwood, Recro Pharma's President and Chief Executive Officer. We believe that having ready access to capital provides us a stronger financial position as we continue our corporate, clinical and operational activities.

Aspire Capital has no right to require any sales by Recro but is obligated to make purchases as Recro directs, in accordance with the terms of the purchase agreement;

There are no limitations on the use of proceeds, financial covenants or restrictions on future financings and there are no rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement; and

The purchase agreement may be terminated by Recro at any time, at its discretion, without any additional cost or penalty.

[protagonist12]

REPH Aegis Capital downgrade

Aegis Capital downgraded Recro Pharma Inc REPH 1.13% Tuesday from Buy to Hold and did not set a price target.

Analyst Yi Chen noted that "Recro Pharma started a Phase 2 clinical trial of Dex-IN, its proprietary intranasal formulation of dexmedetomidine, in late October 2014 in the post-operative Day 1 setting for pain management following bunionectomy surgery."

Regarding the current phase, Chen commented that "though theoretically the Day 1 setting should produce better efficacy than the Day 0 setting, investors ought to be cautious at this point, in our view."

Chen cited a the previous Post Op Day 0 Phase 2 trial in September 2014 in which 95 received Dex-IN "with no serious adverse events, though four patients...discontinued due to symptomatic hypotension and one subject [discontinued] due to fever."

With $23.9 million in cash at the end of September 30, 2014, Chen concluded "that the company shares currently trade at its cash value with a negative enterprise value. If the Day 1 Phase 2 trial reports positive data, the firm may need to raise additional capital by end-2015 for a Phase 3 trial."

Recro Pharma Inc. recently traded at $2.77, down 4.57 percent.

http://www.benzinga.com/analyst-ratings/analyst-color/14/12/5068351/aegis-capital-downgrades-recro-pharma-says-investors-sho

[shankapotamus]

http://thebagholderdiaries.blogspot.com/2014/09/reph-shareholders-vomit-on-news-483.html

[RealGenius]

505(2)(b) program for development of non-opiod post surgical pain drug.

Really, they are just reformulating dexmedetomidine. This is a great non-hypnotic anxiolytic with a 30% narcotic sparing effect. [Established IV medication with lots of data out there]. But as a solo agent for pain? Ehh. This will never be a big sellor even if they demonstrate efficacy. Should be exploring as a pre-op med.